alexa The Physiological Effects of Obesity in HIV-Infected Patients | OMICS International
ISSN 2155-6113
Journal of AIDS & Clinical Research

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

The Physiological Effects of Obesity in HIV-Infected Patients

Krupa Shah1*, Amina P. Alio2, William J. Hall1 and Amneris E. Luque3

1Divisions of Geriatrics and Aging, USA

2Department of Community and Preventive Medicine, USA

3Division of Infectious Disease, University of Rochester School of Medicine and Dentistry, USA

*Corresponding Author:
Krupa Shah MD, MPH
Highland Hospital
Universityof Rochester School of Medicine and Dentistry
1000 South Ave,Rochester
NY 14692, USA
Tel: 584-341-0762
Fax: 584-341-8035
E-mail:[email protected]

Received Date: February 16, 2012; Accepted Date: April 17, 2012; Published Date: April 25, 2012

Citation: Shah K, Alio AP, Hall WJ, Luque AE (2012) The Physiological Effects of Obesity in HIV-Infected Patients. J AIDS Clinic Res 3:151. doi:10.4172/2155-6113.1000151

Copyright: © 2012 Shah K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of AIDS & Clinical Research

Keywords

HIV; Obesity; Older adults; Cardiovascular disease; Frailty

Introduction

Obesity is a medical condition in which excess body fat has accumulated to the extent that it may have an adverse effect on health. More than one-third of U.S. adults (over 72 million people) and 17% of U.S. children are obese. Additionally, obesity rates have markedly increased in population groups, regardless of race, ethnicity, socioeconomic status, education or geographic region [1].

HIV-infected patients mirror the trends in the general population and are increasingly overweight or obese both at diagnosis and during HIV infection [2]. Weight gain in HIV-infected patients appears to reflect improved health status, as severe weight loss and wasting has been traditionally associated with HIV-infected status. However, as seen in the general population, HIV-infected patients also show an association between weight excess and adverse medical consequences. Indeed, obesity leads to the onset of metabolic imbalances. Central adiposity is associated with the metabolic syndrome and related risks for type 2 diabetes mellitus (DM), atherosclerosis, dyslipidemia, hypertension and malignancies [3,4]. The prevalence of these metabolic complications has increased among HIV-infected patients receiving ART and these metabolic complications currently outnumber AIDS associated conditions in these patients and develop at a younger age compared to controls even after adjusting for factors related to HIV disease progression and development of co-morbidities [5,6].

Prospective clinical studies using anthropometric measures have demonstrated. an increase in the proportion of overweight or obese at time of HIV infections and also weight gain over time [2]. Overall rates of obesity in HIV-infected patients are similar to HIV-uninfected controls [7]. Additionally, patients have reported to gain weight during the course of HIV infection [2,7]. Toxicities from prolonged exposure to ART add to the complexity of obesity and are suspected to lead to changes in body composition and metabolic abnormalities.

In light of these trends, this article reviews existing literature on the impact of general obesity on HIV-infected patients and the management of general obesity with a particular focus on aging.

Materials and Methods

Articles published in peer reviewed journals were identified through search strategies using PubMed, OvidSP and MEDLINE. Keywords included: HIV, obesity, weight gain, aging, telomeres, physical function, cardiovascular risk, bone and cognition. These terms were used in combination to address each topic area of interest: impact of obesity in HIV-infected individuals on their immune function/aging, metabolic abnormalities, cognitive function, bone mineral density, physical function and frailty and interventions and management of obesity/ weight gain among HIV infected individuals. These topics were selected to address issues presented as a follow-up to the seminal publication by Guenter et al. [8] that reported on the association between low body weight and a greater relative risk of death before effective antiretroviral therapy became available, providing an important comparator for the work published after the availability of ART. Hence, only articles published in English between 1993 and 2012 were searched for relevance and inclusion in this critical review. References from significant articles led to additional papers to be reviewed, for a total of 65 studies included in this analysis.

Results

Impact of obesity HIV infected individuals

Impact of obesity on the immune system/aging: Before the advent of ART, studies showed that being underweight was associated with lower CD4+ cell counts and shorter survival while higher weights were associated with slower HIV progression [8,9]. The impact of excess weight on the immune system of patients with HIV has not been systematically studied since; few studies have examined the impact of excess weight on the immune system of HIV-infected patients.

The HIV Epidemiology Research (HER) Study examined the association of body mass index (BMI) and HIV disease outcomes in women followed longitudinally [10]. This multicenter epidemiological cohort study reported that the mean CD4+ cell count was progressively higher and the mean log HIV viral load progressively lower as the BMI increased, with no significant difference in age, duration of HIV positivity, income or education by BMI weight group. Regression analysis showed an association between BMI and a risk of HIV disease progression, whether immunological, clinical or mortality related. The improved outcomes were interpreted as associated with higher BMI due to increased fat mass rather than an increase in lean muscle mass. This was endorsed by the fact that the participants were largely poor, inner city women who were unlikely to engage in any systematic exercise or weight training activities, were not pregnant, and were not enrolled in any clinical trials of human growth hormone. The authors proposed that higher levels of leptin, which are in direct proportion to fat cell mass, may be responsible for the potential protective effect of obesity. In support of this explanation, are the facts that CD4+ cells have leptin receptors [11]. Moreover, in vitro studies have demonstrated that the addition of physiologic concentrations of leptin induces a dose dependent increase in the proliferative responses of highly purified CD4+ T-lymphocytes. Along the same note another recent study reported that obese HIVinfected individuals with well suppressed viremia had significantly higher CD3 and CD8 cells and total lymphocyte counts [12].

Telomeres are key markers of cellular and biological aging. With increasing aging a slow and gradual loss of telomere length has been reported [13]. Oxidative stress and inflammation are major contributors to aging and aging related chronic diseases; shorter telomeres have been described in cancer, diabetes, metabolic syndrome, in individuals with increased cardiovascular disease risk factors and in response to psychosocial stress [14]. Studies in humans have shown that high total and abdominal adiposity are directly related to decrease telomere length suggesting that obesity may accelerate the aging process [15]. Telomere length was inversely associated with BMI and waist to hip ratio independent of sex, age, fasting glucose and insulin, lipid and lipoprotein concentration, habitual physical activity, smoking and other metabolic risk factors [15]. These findings support a role of oxidative stress and inflammation in telomere attrition with obesity.

The cause of accelerated aging with HIV disease is subject of much discussion and research at this time, and immune activation and ongoing inflammation are being considered as important potential mechanisms [6,16]. Many HIV-infected patients also have atherogenic lipid profiles which are described as negatively associated with telomere length. Ameliorating persistent inflammation and oxidative stress or finding strategies to decrease adiposity might influence premature aging, and other long term complications in HIV infected patients.

Impact of obesity on metabolic abnormality: In general, obesity causes increased risk of cardiovascular disease (CVD), hypertension, dyslipidemia and DM [17]. Obesity, particularly abdominal obesity, is independently associated with CVD independent of DM, hypertension and dyslipidemia [18]. Further, excessive abdominal fat particularly visceral fat is commonly associated with multiple metabolic abnormalities as part of the “metabolic syndrome”, even in patients with normal BMI [19].

HIV-infected patients appear to frequently develop increased visceral fat and metabolic syndrome after starting ART regimens. Indeed, HIV-infected patients are known to have significantly greater amounts of abdominal fat compared to age -matched HIV-uninfected individuals [20]. Increased upper trunk and abdominal fat has been shown to correlate strongly with insulin resistance and dyslipidemia in HIV-infected patients [21,22]. Similarly, among HIV-infected receiving ART patients, epicardial and visceral fat is significantly associated with the progression of coronary calcium scores, a marker of CVD [23].

HIV-infected patients are prone to a great number of lipid and lipoprotein disturbances, as a result of both the infection itself and direct effects on lipid metabolism. These lipid disorders account for at least part of the increased risk of CVD seen in this population. Additionally, some studies report that the risk of CVD is higher among HIV-infected patients compared to uninfected patients [24,25]. Furthermore, HIVinfected patients who are overweight and obese are at increased risk of CVD [25]. Clinical imaging studies have shown an increased prevalence of subclinical atherosclerosis in HIV-infected patients on ART [26]. A multi-factorial etiology has been proposed to contribute to higher rates of MI and subclinical atherosclerosis in this cohort. This include a state of hypercoagulation or inflammatory changes within the vessel wall or direct damage to endothelial tissues by HIV infection [27]. Further, elevated levels of adipose tissue derived cytokines (adipokines) not only contribute in the initiation and progression of vascular damage, but may also be involved in metabolic abnormalities and fat redistribution/ lipodystrophy associated with HIV infection [28,29]. These adipokines favor the increase of intracellular conversion of inactive cortisone to active cortisol, in adipose tissue; this would cause increased lipolysis and release of FFAs which could then be deposited in ectopic tissues (Figure 1).

Impact of obesity on cognitive function: In the general population, vascular risk factors and obesity play a role in the development of dementia including Alzheimer disease (AD) [30]. In one study, clustering of these vascular risk factors increased the risk of dementia and AD in an additive manner so that persons with all 3 risk factors had around a 6 times higher risk for dementia than persons having no risk factors [31].

Another study contributing to our further understanding of the association between central obesity and the development of dementia is a study of 6,583 continual members of the Kaiser Permanente (KP) Medical Care Program of Northern California (reference). Findings revealed that central obesity is associated with an increased risk of dementia independent of demographics, DM, cardiovascular comorbidities, and BMI [32]. Central adiposity seems to add significant risk even in those who are not overweight. The visceral fat is known to secrete several inflammatory cytokines which are associated with greater cognitive decline [33].

In patients with HIV-infection, the prevalence HIV-associated dementia was estimated at 16% in AIDS cases before the availability of effective ART, while recent estimates indicated a prevalence of less than 5%. Despite this obvious improvement, the neurocognitive responses to effective ART have been varied across individuals and studies of HIV- associated neurocognitive disorders (HAND) have documented persistent rates of mild to moderate neurocognitive impairment [34]. Moreover, there are several reports providing evidence of neuropsychological impairment, abnormal brain electrical activity related to cognition, brain changes detected by MRI or MR spectroscopy, alterations in CSF markers of monocyte activation and CNS injury and brain pathology detected at autopsy. A recent report using MRI to study changes in brain volume in a small group of treated HIV-infected patients showed evidence of continued tissue loss primarily in the white matter that may indicate ongoing brain injury in HIV-infected patients on ART [35].

The causes of continuing high rates of HAND in patients receiving effective ART are unclear. Metabolic abnormalities and associated vascular pathology seem plausible given what is known about the association between central adiposity and dementia in the general population. Central adiposity and metabolic abnormalities are very common in treated HIV-infected patients who are aging. Because these metabolic complications are occurring at an early age in HIV-infected patients than in HIV-uninfected patients, accelerated aging has been proposed [6].

The association between central adiposity, which is common in HIV-infected patients receiving ART who are aging, and cognitive decline, has not been studied in the HIV-infected population.

Impact of obesity on bone mineral density: Numerous studies have shown that lower BMI is independently associated with lower BMD in the general population [36,37]. Studies which focus on HIVinfected patients, confirmed this relationship in this cohort [38,39]. A growing body of literature presents associations between low BMD and both HIV-infection and ART [40,41]. In addition to being associated with low BMD, HIV-infected patients are also at increased risk of bone loss and fragility factures [42,43].

Further, it is known that obesity is associated with increased BMD and decreased osteoporosis and hip fracture in the general population [36]. Body fat mass and lean mass are both directly correlated with BMD. Despite the mechanical burdens that come with obesity-related increases in BMD, one must also acknowledge the protective effects of obesity on non-weight-bearing bones [44]. Hormonal factors that are increased in obese persons, such as circulating estrogens, insulin, and leptin, may contribute to the beneficial effects of obesity on BMD by stimulating bone growth and bone remodeling [45]. The increase in both BMD and the extra cushioning effect of fat adjacent to important areas such as the hip might provide protection against fractures during a fall [46]. Therefore, obesity may provide some beneficial effects to bone health in HIV-infected patients.

Impact of obesity on physical function and frailty: It is commonly known that obesity exacerbates age-related decline in physical function [47,48]. Studies which have looked at the general population demonstrate that obesity is an important cause of frailty. In light of the growing prevalence of obesity, it is not surprising that the most common phenotype of frailty in the years to come is described as the obese, disabled older adult [49]. Given the demographic shift and the rapid increase in the aging population, frailty has been recognized as a major challenge facing the world today. Frailty in the geriatric and gerontology literature is defined as a syndrome of decreased physiological reserve which increases vulnerability to negative outcomes such as loss of independence, increased nursing home admissions, and increased morbidity and mortality [50].

As a result of the advances in ART, the life span of HIV-infected patients has increased dramatically. Attendant to these effects are signs of premature aging with notable changes in the musculoskeletal system. Studies suggest that HIV-infected individuals have reduced physical function, muscle weakness and fatigue, and are at increased risk of frailty [51,52]. In fact, some HIV-infected patients manifest frailty characteristics at a much younger age compared to HIV-uninfected patients with frailty [52], thereby suggesting that the HIV-infected population may experience a form of accelerated aging.

HIV-infected patients with obesity represent an important cohort because this population may be most vulnerable for accelerated functional decline given that HIV-infected patients experience muscle weakness and fatigue in the face of increased body mass [53]. This accelerated functional decline in the HIV-infected patient population is further compounded by the normal aging process.

A recent study evaluated the impact of obesity on physical function in HIV-infected patients compared to non-obese HIV-infected and obese HIV-uninfected [54]. This study found that patients who were both obese and HIV-infected were more impaired in mobility and balance than those who were non obese HIV-infected and obese HIV-uninfected patients. Specifically, HIV-infected obese patients were more impaired in fast gait initiation time and cadence, nonpreferred leg stance time, 360-degree turn time, and sway strategy scores. Another recent study which investigated the functional status and prevalence of frailty and in community-dwelling HIV-infected older adults (HOA, age > 50) demonstrated that greater fat mass and higher BMI is associated with frailty and functional impairment in the HOA population. Moreover, the study found that central obesity and fat redistribution were important predictors of functional status among community-dwelling HOA [55].

Management of obesity in HIV-infected patients

Considering that there is paucity of research in this field, strategies of assessing and managing obesity in HIV-infected patients have been borrowed largely from those that are recommended for the general US population. It is important to examine the differences between HIVinfected population and the general population with regards to obesity measurement and management.

A limitation of using the common methods of measuring obesity (BMI and waist circumference) to estimate disease risk among the HIV-infected is the effect of the disease and antiretroviral therapy (ART) on fat redistribution in patients with normal weight. Risk factors (i.e. visceral fat, intramuscular fat, and intrahepatic fat) for insulin resistance and metabolic diseases increase not only with HIV and ART, but also with aging [56]. The size of these fat depots is therefore more likely to be greater in HIV-infected older patients compared to HIV-infected younger patients and HIV-uninfected older patients at any given BMI. Waist circumference has been found to be an adequate method for estimating intrabdominal fat content or visceral fat [57]. However, because it is common for HIV-infected patients to have increased abdominal girth [29], it is helpful to distinguish whether one’s increased waist circumference is accompanied by other characteristics of lipodystrophy or lipodystrophy syndrome such as altered fat distribution and related metabolic syndrome.

Most studies that have looked at the effects of weight loss on obesity-related medical complications have been done on the general population, among which weight loss therapy is a proven strategy to reduce fat mass, improve obesity related problems and is of minimum complication risks to the patient [58,59]. In the HIV literature, one study presents the results of a small-scale intervention study designed to promote weight loss in obese (BMI > 30) HIV-infected patients [60]. In that study, 18 HIV-infected women completed a 12-week weight loss program (through dietary energy restriction combined with aerobic and resistance exercise) with moderate weight loss (7%). Similar to the results observed in the general population, this study also showed improvement in weight, body composition, strength, and fitness in the HIV-infected patient that completed the intervention. Contrary to the results of the general populations, HIV-patients showed a lack of improved insulin sensitivity and other surrogate markers of cardiovascular risk. There was a high drop-off rate (36%) in this HIVspecific study, which highlights the difficulty of compliance in this unique population. More research is needed, and preferably on a larger scale, to confirm the above-mentioned results.

First of all, HIV-infected populations may have more psychiatric diseases, lacking supportive network, substance abuse issues and socioeconomic challenges [61,62]. Further, HIV-infected patients, and particularly older HIV-infected patients, tend to have multiple co morbidities, cognitive or sensory impairments which can affect their compliance [63,64]. Therefore, targeted research specific to this unique cohort is sorely needed in this field to develop evidence-based guidelines to best manage obesity. Weight management programs have been suggested to achieve successful weight reduction and maintenance in obese HIV-infected patients [2]. However, compliance to strategies to manage or prevent obesity may be more of an issue in HIV-infected patients compared to the general population not only because of the clinical characteristics listed above, but also because of adverse socioeconomic characteristics and/or substance abuse present in many HIV-infected patients [61,62]. Finally, there may be hesitatation in recommending weight loss for HIV-infected patients because advanced HIV infection or poorly treated infection is usually accompanied with unintended weight loss, particularly muscle wasting. There continues to be fear of wasting and some patients take active measures to increase body weight.

Discussion

Although obesity might have a protective effect on HIV disease progression, it has detrimental health consequences, including cardiovascular disease, DM, hyperlipidmia, functional decline and physical frailty. Increased oxidative stress, genetic instability and disturbance of homeostatic pathway are postulated as the mechanism leading to these conditions which are similar to those of obesity and aging.

Our review of the literature suggests that as HIV has become a chronic manageable disease, the prevalence of obesity has increased in the HIV population and is comparable to the general population. While HIV-infected patients are increasingly overweight, we do not completely understand the complications of obesity in HIV-infected patients and its pathophysiologic mechanisms. Moreover, the impact of excess weight on the immune system has not been systematically studied in this population. During the pre-ART era, studies show that being underweight was associated with lower CD4+ cell counts and shorter survival, while higher weights were associated with slower HIV progression. Therefore, obesity might have a protective effect on HIV disease progression. This relationship, however, needs to be confirmed with studies in the post-ART era. Further, the association between obesity and telomere length and its effects on aging should also be investigated in the context of HIV disease.

In the general population, obesity is associated with the development of cognitive decline and dementia. The association between obesity, particularly central adiposity (a common trait in HIV-infected older patients receiving ART), and cognitive decline has not been studied in this cohort. This is important because cognitive impairment is a common problem with HIV-infected older adults and can negatively impact their quality of life [65]. Finally, similar to the general population, HIV-infected patients show an association between central adiposity and adverse medical consequences such as DM, atherosclerosis, dyslipidemia, and hypertension and adipokines have been implicated as a mediator of this relationship.

HIV-infected patients have reduced physical function and are at increased risk of frailty. Frailty in HIV-infected patients was previously conceptualized as being a wasting disorder. In the pre-ART era, frailty in HIV-infected patients was commonly observed in the setting of wasting and immunocompromised states with lower CD4 count. In the post-ART era, obesity is seen to be a possible important determinant of functional decline and frailty in community-dwelling HIV-infected patients. The effects of obesity on HIV disease and aging may worsen and increase the risk for functional decline and frailty-related poor outcomes.

Weight-loss therapy is a proven strategy to reduce fat mass and improve obesity-related problems. However, there is a paucity of literature in managing obesity in HIV-infected patients. While it seems reasonable to expect that a significant proportion of HIV-infected patients will respond to conventional weight management strategies for improved clinical outcomes, it is unclear whether such strategies are practical or even effective in this population where non-compliance could be a major issue. Finally knowledge of obese status and acceptance of obese status may vary by gender and ethnicity among HIV infected adults, similar to the general population.

Conclusion

Recent reports on the in the prevalence of overweight and obesity in HIV-infected patients emphasize the need for greater attention to early evaluation and subsequent management strategies. Although, we do not fully understand the pathophysiologic mechanisms and complications of obesity in HIV-infected patients, it appears that obesity has important functional implications in HIV disease because it can exacerbate the HIV and aging-related decline in physical function and even cause frailty. Therefore, it is important to consider customized weight management strategies to improve physical function in obese older persons, in addition to possibly preventing or improving the medical complications associated with obesity. While it is intuitive that a significant proportion of HIV-infected patients will respond to conventional weight management strategies, it is unclear whether such strategies are most effective, especially for better clinical outcomes and long-term maintenance. Therefore, future research is urgently needed to develop evidence-based guidelines to assess and manage obesity in HIV-infected patients, and particularly those who have functional impairments or medical complications that can benefit from individualized weight management programs.

Acknowledgements

This work is supported by John A Harford Foundation Center for Excellence in Geriatric Medicine and Training , and the University of Rochester Developmental Center for AIDS Research grant P30 AI078498 (NIH/NIAID).

Contribution

Krupa Shah and Amneris E. Luque designed this project, researched, and wrote drafts of the paper. Krupa Shah integrated contributions and prepared the manuscript for submission. Amina Alio and William J. Hall edited the paper. All authors contributed to and approved the final version of the paper.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Recommended Conferences

  • 6th World Congress on Control and Prevention of HIV/AIDS , STDs & STIs
    August 27-29, 2018 Zurich, Switzerland
  • 6th International Conference on HIV/AIDS , STDs and STIs
    October 29-30, 2018 San Francisco, USA

Article Usage

  • Total views: 12491
  • [From(publication date):
    April-2012 - Jun 19, 2018]
  • Breakdown by view type
  • HTML page views : 8647
  • PDF downloads : 3844
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7